Funding sources: Supported by the Wright Foundation.Conflicts of interest: Dr Wysong serves as an unpaid scientific advisor for Castle Biosciences. Ms Lobl, Drs Clarey and Higgins, and Ms Thieman have no conflicts of interest to declare.IRB approval status: All studies were approved by the instituutional review board.

<b><i>Introduction:</i></b> Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with various comorbidities and diminished quality of life (QoL). Among dermatological conditions, HS is reported to most severely diminish QoL. This study aimed to analyse the health-related QoL (HRQoL) of patients with HS in more detail by using generic to disease-specific HRQoL questionnaires. Correlations between the HRQoL measures and HS disease severity measures were assessed. <b><i>Methods:</i></b> We analysed the HRQoL and clinical severity of patients with HS (<i>N</i> = 92) treated in 5 Finnish hospitals using HRQoL measurement tools most often used in dermatological clinics, as well as the generic 15D instrument (standardized and self-administered 15-dimensional measure of HRQoL). The disease severity was assessed using the Hurley stage, International Hidradenitis Suppurativa Severity Score System, and disease severity evaluation by the investigator. <b><i>Results:</i></b> The mean 15D score of HS patients was low and comparable with that of patients with cancers. No correlation was found between HS severity measures and 15D score, indicating that even mild HS has a high impact on HRQoL. <b><i>Conclusions:</i></b> Our findings strengthen the understanding about HS as a debilitating disease and even compared with non-dermatological conditions and highlight the need of comprehensive care of patients with HS.

OBJECTIVES: Lichen planus is a dermatological disease characterized by itchy reddish-purple polygon-shaped skin lesions. The aim of our study was to calculate the annual health insurance treatment cost of lichen planus in Hungary. METHODS: The data were derived from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFA), the only health care financing agency in Hungary. We analyzed the number of patients and the health insurance treatment cost for the year 2017. The following cost categories were included into the study: out-patient care, laboratory diagnostics, medical imaging, acute in-patient care, chronic in-patient care and drugs. Patients with lichen planus were identified with the following codes of the International Classification of Diseases 10threvision: L43. RESULTS: The number of patient underwent outpatient care was 3,013 (59.8 % women and 40.2 % men) with a mean age of 54.90 years (women: 57.56 years; men: 50.94 years). Number of patients admitted to in-patient hospital care was 145 (75.9 % women and 24.1 % men) with a mean age of 61.48 years (women: 64.42 years; men: 52.23 years). For the treatment of patients with lichen planusin 2017 the Hungarian National Health Insurance Fund Administration spent 57.282 million Hungarian Forint (HUF) which equals 185.255 Euro (EUR). Major cost drivers were acute inpatient care (35.6 % of total health insurance costs), outpatient care (28.1 %) and pharmaceuticals (26.8 %). CONCLUSIONS: Lichen planus represent a significant burden for the Hungarian health insurance system. The occurrence of the disease is more common in women both in outpatient and inpatient care. There is a significant difference (outpatient: 6.61 years; inpatient: 12.19 years) in the onset of the disease between women and men.